Transporting neonates with nitric oxide: The 5-year ShandsCair experience

Air Medical Journal

Volumn 23, Issue 1, 2004, Pages 17-19

  Jesse, Nate M ^a   Drury, Lynn ^b   Weiss, Michael D ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b ShandsCair Flight Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; OXYGEN;

ANTICOAGULATION; ARTICLE; ARTIFICIAL VENTILATION; CANNULATION; CONGENITAL DIAPHRAGM HERNIA; DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EXTRACORPOREAL OXYGENATION; HIGH FREQUENCY VENTILATION; HUMAN; INTENSIVE CARE; LUNG HYPOPLASIA; MECONIUM ASPIRATION; MORBIDITY; NEWBORN; NEWBORN DISEASE; NEWBORN HYPOXIA; NEWBORN INTENSIVE CARE; PATIENT TRANSPORT; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; RISK ASSESSMENT; SEDATION;

EID: 1342269071     PISSN: 1067991X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amj.2003.10.001     Document Type: Article

References (14)

1. Holowaty L. Nitric oxide. Neonatal Netw 1995;14(6):83-6.
2. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987;84:9265-9.
3. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
4. Furghott R, Zawadki J. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetocholine. Nature 1980;288:373-6.
5. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:819-20.
6. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:818-9.
7. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997;336:597-604.
8. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000;342:469-74.
9. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, et al. Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. Pediatrics 1999;104(2 Pt 1):231-6.
10. Kinsella JP, Schmidt JM, Griebel J, Abman SH. Inhaled nitric oxide treatment for stabilization and emergency medical transport of critically ill newborns and infants. Pediatrics 1995;95:773-6.
11. Kinsella JP, Griebel J, Schmidt JM, Abman SH. Use of inhaled nitric oxide during interhospital transport of newborns with hypoxemic respiratory failure. Pediatrics 2002;109:158-61.
12. Torosian MB, Statter MB, Arensman RM. Extracorporeal membrane oxygenation. 3rd ed. Philadelphia: W.B. Saunders; 1988.
13. Gamella TL. Neonatology: management, procedures, on-call problems, diseases, and drugs. 4th ed. New York: Lange Medical Books; 1999.
14. Prevention CfDCa. Recommendations for occupational safety and health standards. MMWR Morb Mortal Wkly Rep. 1988;37:s7-s21.